Look Out Bell Labs! Here Comes NEC

In the last decade, the Japanese have succeeded in convincing their competitors in the world market that the old saw—that the Japanese can imitate, not innovate—no longer cuts the mustard. But it would appear that they have yet to convince themselves. For while any expert in global economics would say that the Japanese are capable of doing a lot more than simply knocking off United States inventions and turning those knockoffs into irresistibly cheap and sought-after exports, the Jap

Written byJohn Schwartz
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

For while any expert in global economics would say that the Japanese are capable of doing a lot more than simply knocking off United States inventions and turning those knockoffs into irresistibly cheap and sought-after exports, the Japanese keep worrying that their island culture stifles creativity.

This lack of confidence that they can compete with the U.S. in innovation has caused the Japanese to make changes in every level of enterprise—with many of these experiments ironically imitative of U.S. techniques. The government, for example, studied U.S. science parks and spurred the creation in its homeland of vast technology innovation centers such as the 7,000-scientist "science city" of Tsukuba, northeast of Tokyo. On a corporate scale, Japanese management has in recent years tried to modify some aspects of its traditional, highly structured corporate environment—sponsoring idea contests, for example, and, in a nod to Silicon Valley, encouraging casual dress and office surroundings ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies